Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors

Immunotherapy with bispecific T cell engagers has shown efficacy in patients with hematologic malignancies and uveal melanoma. Antitumor effects of bispecific T cell engagers in most solid tumors are limited due to their short serum half-life and insufficient tumor concentration. We designed a novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Basnet, Saru, Santos, Joao M., Quixabeira, Dafne C.A., Clubb, James H.A., Grönberg-Vähä-Koskela, Susanna A.M., Arias, Victor, Pakola, Santeri, Kudling, Tatiana V., Heiniö, Camilla, Havunen, Riikka, Cervera-Carrascon, Victor, Sorsa, Suvi, Anttila, Marjukka, Kanerva, Anna, Hemminki, Akseli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842968/
https://www.ncbi.nlm.nih.gov/pubmed/36699617
http://dx.doi.org/10.1016/j.omto.2022.12.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842968/
https://www.ncbi.nlm.nih.gov/pubmed/36699617
http://dx.doi.org/10.1016/j.omto.2022.12.007

Ejemplares similares